LABA

Olodaterol

Brand names: Striverdi Respimat

Olodaterol is an inhaled long-acting beta-2 agonist (LABA) used as maintenance bronchodilator therapy in chronic obstructive pulmonary disease.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively stimulates beta-2 adrenoceptors on airway smooth muscle, causing sustained relaxation and bronchodilation.

Prescribing in practice

It is a long-acting maintenance bronchodilator and must not be used for relief of acute bronchospasm or as monotherapy in asthma.
Use with caution in cardiovascular disease and conditions sensitive to beta-agonists, and be aware of the risk of hypokalaemia.
It is frequently prescribed in a fixed-dose combination inhaler with a long-acting antimuscarinic for COPD.

Monitoring

Monitor symptom control, lung function and exacerbation frequency, and remain alert to tachycardia, tremor and hypokalaemia.

Counselling the patient

Use this inhaler regularly to keep your airways open, not for sudden breathlessness.
Keep a separate fast-acting reliever inhaler for emergencies.
Report palpitations, marked tremor or muscle cramps.

Evidence & guidelines

Long-acting beta-2 agonists are an established maintenance treatment for COPD within NICE and GOLD guidance.

Reference: NICE NG115; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Pathways